vs
Side-by-side financial comparison of enCore Energy Corp. (EU) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $12.4M, roughly 1.1× enCore Energy Corp.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -173.9%, a 249.6% gap on every dollar of revenue. enCore Energy Corp. produced more free cash flow last quarter ($7.2M vs $-2.1M).
Devon Energy Corporation is an American company engaged in hydrocarbon exploration. It is organized in Delaware with operational headquarters in the 50-story Devon Energy Center in Oklahoma City, Oklahoma. Its operations are in the Delaware Basin, Eagle Ford Group, and the Rocky Mountains.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
EU vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.4M | $13.7M |
| Net Profit | $-21.5M | $10.4M |
| Gross Margin | 37.9% | — |
| Operating Margin | -135.9% | -86.5% |
| Net Margin | -173.9% | 75.7% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 179.1% |
| EPS (diluted) | $-0.11 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.4M | $13.7M | ||
| Q3 25 | $8.9M | $19.1M | ||
| Q2 25 | $3.7M | $8.1M | ||
| Q1 25 | $18.2M | $2.9M |
| Q4 25 | $-21.5M | $10.4M | ||
| Q3 25 | $-4.8M | $-16.3M | ||
| Q2 25 | $-6.3M | $-15.8M | ||
| Q1 25 | $-24.2M | $-13.3M |
| Q4 25 | 37.9% | — | ||
| Q3 25 | 43.8% | — | ||
| Q2 25 | 30.8% | — | ||
| Q1 25 | -0.1% | — |
| Q4 25 | -135.9% | -86.5% | ||
| Q3 25 | -158.2% | -10.1% | ||
| Q2 25 | -526.1% | -177.7% | ||
| Q1 25 | -85.7% | -472.7% |
| Q4 25 | -173.9% | 75.7% | ||
| Q3 25 | -53.7% | -85.4% | ||
| Q2 25 | -172.7% | -196.0% | ||
| Q1 25 | -132.9% | -452.7% |
| Q4 25 | $-0.11 | $-3.74 | ||
| Q3 25 | $-0.03 | $-0.11 | ||
| Q2 25 | $-0.03 | $-0.16 | ||
| Q1 25 | $-0.13 | $-0.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $137.5M |
| Total DebtLower is stronger | $110.0M | — |
| Stockholders' EquityBook value | $229.2M | $35.3M |
| Total Assets | $430.4M | $154.7M |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $137.5M | ||
| Q3 25 | $91.9M | $103.8M | ||
| Q2 25 | $26.9M | $121.6M | ||
| Q1 25 | $29.7M | $89.1M |
| Q4 25 | $110.0M | — | ||
| Q3 25 | $109.3M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q4 25 | $229.2M | $35.3M | ||
| Q3 25 | $248.6M | $-8.1M | ||
| Q2 25 | $264.7M | $7.1M | ||
| Q1 25 | $267.9M | $10.7M |
| Q4 25 | $430.4M | $154.7M | ||
| Q3 25 | $441.9M | $133.7M | ||
| Q2 25 | $359.4M | $133.8M | ||
| Q1 25 | $362.6M | $103.7M |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.44× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.9M | $-2.0M |
| Free Cash FlowOCF − Capex | $7.2M | $-2.1M |
| FCF MarginFCF / Revenue | 57.8% | -15.3% |
| Capex IntensityCapex / Revenue | 46.7% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-45.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.9M | $-2.0M | ||
| Q3 25 | $-20.3M | $-17.5M | ||
| Q2 25 | $-9.9M | $-14.5M | ||
| Q1 25 | $-7.7M | $29.0M |
| Q4 25 | $7.2M | $-2.1M | ||
| Q3 25 | $-26.3M | — | ||
| Q2 25 | $-14.1M | $-14.9M | ||
| Q1 25 | $-11.7M | $29.0M |
| Q4 25 | 57.8% | -15.3% | ||
| Q3 25 | -296.6% | — | ||
| Q2 25 | -385.2% | -184.0% | ||
| Q1 25 | -64.1% | 988.3% |
| Q4 25 | 46.7% | 0.7% | ||
| Q3 25 | 68.0% | 0.0% | ||
| Q2 25 | 115.1% | 5.0% | ||
| Q1 25 | 21.7% | 0.8% |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
